Global clinical trial activity in metastatic castration-resistant prostate cancer from January 2020 to March 2026: a landscape analysis
Metastatic castration-resistant prostate cancer (mCRPC) remains a lethal stage of prostate cancer with poor prognosis. Clinical trials for mCRPC are growing rapidly worldwide. However, a comprehensive systematic analysis of the global research and development landscape in mCRPC remains lacking. This study qu...